Dispensing robot can automate intravenous drug dispensing tasks instead of humans, effectively improve the accuracy of drug dispensing, reduce occupational exposure and lower the mechanical repetitive labor intensity of dispensing personnel. However, the use of dispensing robot in China is still in the exploratory stage, the time for its clinical application is relatively short, and the technology is not fully mature. This article reviews the literature related to the application practice of drug dispensing robot, summarizes its application status and technical characteristics and proposes some suggestions for its improvement in view of its existing problems, so as to provide reference for the continuous improvement of the automatic intravenous drug dispensing ability. Medical institutions can choose different types of dispensing robots according to their needs and circumstances.

Objective: To investigate the dosage accuracy of the intravenous infusion with a dispensing robot in pharmacy intravenous admixture service (PIVAS) to ensure medication efficacy. Methods: Ceftriaxone sodium injection, a commonly used antimicrobial drug in clinic, was selected as the research subject, and the HPLC was used to analyze the compliance rate of drug concentration of finished infusion solutions prepared by dispensing robots compared to those prepared manually. Results: The qualified rate of the finished infusion prepared by the dispensing robot was 95.2% compared with that of the finished infusion prepared manually. Conclusion: Dispensing robot can replace the manual automatic completion of intravenous drug dispensing tasks, and ensure the dispensing accuracy and has the effect of improving the occupational protection and effectively reducing the personnel mechanical repetitive heavy labor intensity, which can be popularized and applied on a large scale in PIVAS in China.

Individualized medicine is the cornerstone of precision medicine, while therapeutic drug monitoring is a crucial part of individualized medicine. According to the clinical needs, the Department of Pharmacy of our hospital relies on the therapeutic drug monitoring platform to carry out individualized medication practices and explorations around antimicrobials and immunosuppressants, so as to empower individualized drug therapy development of precision medicine, enhance the refined management of pharmaceutical services and strengthen the professional influence of the discipline.

The pharmacokinetic and pharmacodynamic processes in neonates differ markedly from those in adults, primarily due to underdeveloped organ systems. Additionally, substantial variability exists among individual neonates. Traditional methods for calculating drug dosages often inadequately account for these individual differences, leading to risks of treatment failure or adverse drug reactions. The widespread off-label use of medications in this population highlights the urgent need for personalized medication strategies. Model-informed precision dosing (MIPD) integrates mathematical models with individual physiological data to optimize dosing regimens, further refined through therapeutic drug monitoring for tailored treatment. MIPD shows significant promise in the administration of antibiotics, analgesics, and antiepileptic medications in neonates. However, challenges remain, including difficulties in clinical data acquisition and the limited accuracy of existing mathematical models.

Vitamin K₁ is a fat-soluble vitamin that is essential for the coagulation mechanism in neonates, especially in the process of hepatic synthesis of coagulation factors Ⅱ, Ⅶ, Ⅸ and Ⅹ. However, neonates are often at risk of bleeding disorders due to insufficient endogenous synthesis of vitamin K₁, so supplementation is generally recommended. On the other hand, the use of vitamin K₁ is not without risk, and its labeling mentions that adverse effects such as hyperbilirubinemia, jaundice and hemolytic anemia may occur in neonates. This article analyzes the adverse reactions and possible causes of its use in neonates, and evaluates the safety of vitamin K₁, so as to provide a basis for the safety of its clinical application in neonates.